Menu
Not yet recruiting NCT06975813

Magnesium Sulfate and Trigger Points

Phase II Interventional Myofascial Pain Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: masseter muscle, masseter and sternocleidomastoid muscle.
Who it may be relevant to
Registry conditions: Myofascial Pain Syndrome. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Efficacy of Isolated Masseter Versus Masseter- Sternocleidomastoid Trigger Points Injection by Magnesium Sulfate for Myofacial Pain

Overview

The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter \&sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever

Interventions

  • Drug masseter muscle
    masseter muscle trigger points injection by magnesium sulphate
  • Drug masseter and sternocleidomastoid muscle
    masseter and sternocleidomastoid muscle trigger points injection by magnesium sulphate

Primary outcome measures

  • muscle pain [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • definite diagnosis of myofascial pain
  • presence of one or more unilateral or bilateral trigger points in the masseter muscle and sternocleidomastoid muscle;
  • no history of any invasive procedures of the related masseter muscle.

Exclusion criteria

  • any painful conditions (other than myofascial trigger points) affecting the orofacial region
  • any systemic diseases that could masticatory function (e.g., rheumatoid arthritis and epilepsy);
  • pregnancy and lactation

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06975813 · 1111

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗